NIH sickle cell partner AesRx moves up the food chain in Baxter buyout

John Carroll Having played a pioneering role collaborating with the NIH on a new drug for sickle cell disease, Newton, MA-based AesRx has moved up the food chain after completing a ...

M&A spotlight: Allergan plots cost cuts to ward off Valeant, AbbVie may have to raise Shire bid–again

Carly Helfand Allergan can't stop Valeant from attempting to round up enough support to call a special meeting, overturn its board and strike its takeover defenses. But it can make ...

‘Unpromising’ Allergan drug projects headed for the chopping block–report

John Carroll Allergan execs have made no secret of the fact that they've been planning to come up with a lean-and-mean game plan designed to prove to investors that they'd ...

Pfizer yanks 220,000 Pristiq bottles on pill mix-up

Tracy Staton For the second time in recent months, Pfizer is recalling hundreds of thousands of bottles of a drug when one was found to contain the wrong tablet. FiercePharma News

Bayer likes all the brands it got from Merck, Coppertone and Dr. Scholl’s included

Carly Helfand Should Bayer sell some of the consumer brands it's buying from Merck in a $ 14 billion deal? Analysts say a few of them–Coppertone sun products, for instance–don't ...

Shire laments hole in EU food chain, Late-stage hit for GSK & Genmab, Lundbeck drug flunks PhIII

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. With the battle for investor support in the AbbVie-Shire takeover tug of war heating up, the Ireland-headquartered ...

Alkermes sues Boston biotech startup for trademark infringement

Emily Mullin Startup Alkeus is being sued by Irish drugmaker Alkermes for trademark infringement. According to the Boston Business Journal, the 25-year-old Alkermes filed the lawsuit ...

Trevi, Complexa bag $38M in VC cash to hit the gas on R&D

Damian Garde Two biotech startups have hauled in a combined $ 38 million in Series B funding, pledging to advance their programs in inflammation and skin disease. FierceBiotech News

Novartis nabs Merck exec Bruno Strigini to head up oncology business

Tracy Staton Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit. FiercePharma News

Pfizer’s vows fall on deaf ears in Cambridge

Damian Garde Pfizer, as part of its plodding effort to win over national leaders with its plan to buy AstraZeneca for more than $ 100 billion, has promised to preserve jobs in the ...

U.K. court cuts Alimta exclusivity short, threatening Lilly’s European sales

Tracy Staton Eli Lilly lost a patent fight with Actavis in English High Court, in a ruling that paves the way for copycat competition not only in that country, but several others ...

Can payers get to ‘rational’ hep C drug prices without a price war?

Tracy Staton Payers worried about hepatitis C drug prices have been counting on impending price competition to save them money. The idea is that, once Merck, AbbVie and Bristol-Myers ...
Page 10 of 32« First...89101112...2030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS